Quantitative target engagement of RIPK1 in human whole blood via the cellular thermal shift assay for potential pre-clinical and clinical applications
Shitalben Patel(AbbVie (United States)), James E. Kath(AbbVie (United States)), Joseph T. Klahn(AbbVie (United States)), Frank Gambino(AbbVie (United States)), Sarah Sandoz(Pelago Bioscience (Sweden)), Jon Williams(AbbVie (United States)), Christina K. Baumgartner(AbbVie (United States)), Marie Karlsson(Pelago Bioscience (Sweden)), Helena Costa(CRUK Lung Cancer Centre of Excellence), Kathleen A. McGuire(AbbVie (United States))
Cited by 1
Related Papers
Melanoma and microbiota: Current understanding and future directions
|Cancer Cell|2023|78
Peptide-MHC Class II Complex Stability Governs CD4 T Cell Clonal Selection
|The Journal of Immunology|2009|46
Immune tolerance induced by platelet‐targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated
|Journal of Thrombosis and Haemostasis|2017|34